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In Afghanistan, childhood deaths from pneumonia are high. 
Among 639 children at 1 hospital, the case-fatality rate was 
12.1%, and 46.8% of pneumococcal serotypes detected 
were covered by the 13-valent vaccine. Most deaths oc-
curred within 2 days of hospitalization; newborns and mal-
nourished children were at risk. Vaccination could reduce 
pneumonia and deaths.
In Afghanistan, the mortality ratio for children <5 years of age is 90 deaths/1,000 live births, twice the global 
average; 20% of deaths are from pneumonia (1). Although 
Afghanistan is considered 1 of the 5 countries with the 
highest level of childhood deaths from pneumonia, stud-
ies of the risk factors for death and etiology of pneumonia 
among children in Afghanistan are lacking (2). We there-
fore determined risk factors for death from pneumonia in 
children <5 years of age in a regional hospital in Afghani-
stan and the distribution of pneumococcal serotypes car-
ried in the nasopharynx.
The Study
From December 2012 through the second week of March 
2013, we conducted a prospective observational study in 
the Department of Pediatrics in Abu Ali Sina Balkhi Re-
gional Hospital, Mazar-e-Sharif, Afghanistan, a 700-bed 
regional referral hospital for Balkh Province. This study 
was conducted before pneumococcal conjugate vaccine 
13 (PCV13) had been introduced in Afghanistan. We en-
rolled children <5 years of age who met the World Health 
Organization (WHO) criteria for clinical pneumonia at the 
time of admission (3). We collected data by standardized 
questionnaire and determined immunization status by his-
tory, immunization report, and bacillus Calmette–Guérin 
(BCG) scar.
Malnutrition was defined as weight-for-age z score <-2 
(WHO Anthro software version 3.2.2, http://www.who.int/
childgrowth/software/en/). Anemia in children >6 months 
of age was determined by hemoglobin cutoff values estab-
lished by WHO (4) and in children <6 months by hemoglo-
bin value <2 SDs below the mean for age group (5). Illness 
severity was classified by WHO criteria (3). Hospital out-
comes were classified as discharged (discharged after suc-
cessful treatment), deceased (died during hospitalization), 
and unknown (still in hospital at study end). Children with 
unknown status were excluded from risk factor analysis. 
Neonates/newborns and infants were defined as children <1 
and <12 months of age, respectively.
We collected nasopharyngeal samples according to 
the WHO protocol by using flocked swabs (Copan Diag-
nostics, Murireta, CA, USA) that were stored in STGG 
(skim milk, tryptone, glucose, and glycerine) media at 
–10°C and transferred within 1 month by airplane with 
cold ice packs in a thermos to Nagasaki, Japan, where 
they were stored at –20°C. DNA was extracted by using 
a QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Ger-
many). Streptococcus pneumoniae was detected by lytA 
real-time PCR (selective for autolysin gene), and serotyp-
ing was performed by a nanofluidic real-time PCR that 
detects 50 serotypes as individual serotype/serogroup in-
cluding all vaccine serotypes (6). 
We considered samples positive by lytA PCR but 
negative for serotypes/serogroups nontypeable and co-
colonization with multiple serotypes to be presence of 
>2 serotypes/serogroups in a sample. The percentage of 
vaccine serotypes was calculated as the proportion of 
samples that had a vaccine serotype (including minor se-
rotypes in co-colonization) among samples positive by 
lytA PCR.
For analyses we used Epi Info version 7 (Centers for 
Disease Control and Prevention, Atlanta, GA, USA) and 
Stata 12 (StataCorp LLP, College Station, TX, USA). In 
the univariate analysis model, we included risk factors 
for death from pneumonia at p<0.2, and in the multivari-
ate model we included age, sex, and ethnicity. The study 
complied with STROBE (https://strobe-statement.org/
fileadmin/Strobe/uploads/checklists/STROBE_checklist_
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v4_combined.pdf) guidelines and was approved by the 
Nagasaki University Institutional Review Board, Nagasa-
ki, Japan, and the Balkh Public Health Department, Balkh, 
Afghanistan. Written informed consent was obtained from 
the parents of enrolled children.
Parents of 670 children were approached, and 639 
children were enrolled (online Technical Appendix Fig-
ure 1, https://wwwnc.cdc.gov/EID/article/23/8/15-1550-
Techapp1.pdf). Median patient age was 5.0 (interquartile 
range 2.5–9.0) months; 82.5% were infants and 64.3% 
were male (Table 1). Pneumonia case-fatality ratio (CFR) 
was 12.1% (75/617; 95% CI 9.6%–14.9%) (online Tech-
nical Appendix Table 1). A total of 61 (81.3%) children 
died within 2 days of hospitalization (Figure 1), and most 
were infants (online Technical Appendix Figure 2).
According to univariate analysis, risk for death was 
increased among newborn (odds ratio [OR] 11.1) and mal-
nourished (OR 2.06) children (Table 2). Protective fac-
tors were receipt of BCG vaccine (OR 0.39), >1 dose of 
pentavalent vaccine (OR 0.53), and vitamin A (OR 0.39). 
Among malnourished children, female sex was associated 
with death (online Technical Appendix Table 2). We found 
no significant differences by sex in terms of epidemiolog-
ic, clinical, and nutritional status (data not shown). BCG 
vaccination was independently associated with decreased 
risk for death among patients with pneumonia (Table 2) 
and among malnourished children with pneumonia (online 
Technical Appendix Table 2).
We obtained nasopharyngeal samples from 326 chil-
dren (online Technical Appendix Figure 1). From half 
(49.9%) of the children, samples could not be taken because 
of disease severity; CFR was 18.3% for these children, who 
were more likely to be malnourished and to have received 
antimicrobial drugs before hospitalization (online Techni-
cal Appendix Table 3). S. pneumoniae was detected in 124 
(38.0%) of the 326 samples; 24 serotypes/serogroups were 
identified (Figure 2). Most (87.8%) children had received 
antimicrobial drugs before admission, which, along with 
difficulty storing samples at the research site, influenced 
detection of pneumococci. The proportions of colonization 
were 35.9% among children who received antimicrobial 
drugs before hospitalization and 48.8% among children 
who did not (p = 0.11). The proportion of samples that had 
serotypes covered by 7-, 10-, and 13-valent pneumococcal 
conjugate vaccines were 39.5%, 39.5% and 46.8%, respec-
tively. Co-colonization with multiple serotypes occurred in 
21 (16.9%) of 124 positive samples.
Conclusions
The CFR for children <5 years of age with pneumonia ad-
mitted to a regional hospital in Afghanistan was 12.1%, 
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Table 1. Characteristics and clinical outcomes for 639 children 
<5 years of age with pneumonia hospitalized at Ali Sina Balkhi 
Regional Hospital, Mazar-e-Sharif, Afghanistan, December 
2012–March 2013 
Characteristics No. (%) 
Sex  
 M 411 (64.3) 
 F 228 (35.7) 
Age, mo  
 <1 (newborn) 17 (2.7) 
 1–11  510 (79.8) 
 >12  112 (17.5) 
Maternal illiteracy 549 (85.9) 
Duration of illness >7 d before hospitalization 102 (16.0) 
Ethnicity 
 
 Tajik 300 (46.9) 
 Pashtoon 123 (19.3) 
 Uzbek 77 (12.0) 
 Hazara 101 (15.8) 
 Other 38 (6.0) 
Received antimicrobial drugs before hospitalization  
 Yes 561 (87.8) 
 No 65 (10.2) 
 Unknown 13 (2.0) 
Vaccination status, vitamin A intake, and nutritional status 
 Bacillus Calmette–Guérin vaccine 545 (85.2) 
 >1 dose of pentavalent vaccine, n = 568 436 (76.8) 
 Measles vaccine, n = 171 107 (62.6) 
 >1 dose of vitamin A, n = 345 119 (34.5) 
Malnutrition* 
 
 Detected 255 (39.9) 
 Not detected 381 (59.6) 
 Not evaluated 3 (0.5) 
Anemia† 
 
 Detected 296 (46.3) 
 Not detected 220 (34.4) 
 Not evaluated 123 (19.3) 
Both malnutrition and anemia, n = 514 126 (24.5) 
Very severe pneumonia‡ 532 (83.3) 
Clinical outcome, n = 617 
 
 Discharged well 542 (87.9) 
 Death 75 (12.1) 
*Defined by weight/age z score <–2, and the z score value was calculated 
by using World Health Organization Anthro software, version 3.2.2 9 
(http://www.who.int/childgrowth/software/en/). 
†Defined according to the World Health Organization (4) and Janus et al. 
(5). 
‡Severity classified according to World Health Organization (3). Very 
severe pneumonia is defined as cough or difficulty breathing with 1 of the 
following: central cyanosis, difficulty feeding, convulsions, lethargy, loss of 
consciousness, severe respiratory distress. 
 
Figure 1. Proportion of deaths and days of hospitalization among 
children <5 years of age with pneumonia admitted to Abu Ali Sina 
Balkhi Regional Hospital, Mazar-e-Sharif, Afghanistan, December 
2012–March 2013. 
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compared with only 7.6% for the full WHO Eastern Medi-
terranean region (7). Most deaths occurred within 2 days 
of hospitalization. Factors that may have contributed to the 
high mortality rate were delays in presentation to health-
care facilities, inability to identify severe symptoms in 
children, and delayed referral from primary care (7). These 
issues could be addressed by strengthening the Integrated 
Management of Childhood Illness program of WHO, intro-
duced in Afghanistan in 2004 (8).
Our finding that newborns and children with malnu-
trition were at increased risk for death is consistent with 
findings of studies in India and Pakistan (9,10). These 
risks could be reduced by use of clean delivery kits, 
clean delivery practices, exclusively breast-feeding, 
education about complementary feeding, and provision 
of complementary foods in regions where food is less 
secure (11,12). 
BCG vaccination was protective. Neonatal BCG vac-
cination is known to be associated with reduced rates of 
childhood death, respiratory infection, and sepsis, probably 
by nonspecific immune effects (13); it can also be a proxy 
for better access to healthcare, immunization, and unmea-
sured favorable factors. 
Female sex was significantly associated with death 
among malnourished children, which was not explained 
by association with other variables. A higher incidence of 
acute lower respiratory infection in male children, particu-
larly in southern Asia, was reported in a recent systematic 
review, but the pneumonia CFR was higher in girls than in 
boys <1 year of age (7).
With support from the Global Vaccine Alliance, 
WHO, and the United Nations Children’s Fund, PCV13 
was introduced in Afghanistan in January 2014. Our study 
detected a wide variety of serotypes, including nonvaccine 
serotypes. Vaccine coverage was comparable with that 
found by regional studies (14,15). Serotype data are lim-
ited by the short study duration, common use of antimi-
crobial drugs before hospitalization, and difficult storage 
of samples.
The high rate of death from pneumonia among chil-
dren could be reduced by strengthening existing public 
health programs (e.g., Integrated Management of Child-
hood Illness, nutrition programs, and immunization pro-
grams). Although the proportion of serotypes covered by 
PCV13 vaccines was 46.8%, PCV13 could still prevent 
many cases of pneumonia and deaths among children 
in Afghanistan.
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Table 2. Risk factors for death from pneumonia among children <5 years of age hospitalized at Abu Ali Sina Balkhi Regional Hospital, 
Mazar-e-Sharif, Afghanistan, December 2012–March 2013 
Variable 
Discharged,  
no. (%), n = 542 
Deceased,  
no. (%), n = 75  
Odds ratio  
(95% CI) p value 
Adjusted odds 
ratio (95% CI)* p value 
Sex       
 F 186 (34.3) 32 (42.7) 1.42 (0.87–2.32) 0.15 1.61 (0.96–2.71) 0.06 
 M 356 (65.7) 43 (57.3) 1  1  
Age, mo       
 <1 (newborn) 9 (1.7) 8 (10.7) 11.1 (3.36–36.6) <0.01 13.1 (3.71–46.5) <0.01 
 1–11  433 (89.9) 59 (78.6) 1.70 (0.78–3.67) 0.17 1.59 (0.72–3.49) 0.24 
 >12  100 (18.4) 8 (10.7) 1    
Maternal illiteracy       
 Literate 83 (15.3) 7 (9.3) 0.56 (0.25–1.28) 0.17 0.62 (0.26–1.45) 0.27 
 Illiterate 459 (84.7) 68 (90.7) 1    
Duration of illness, d       
 >7  80 (14.8) 17 (22.7) 1.56 (0.85–2.85) 0.14 1.73 (0.92–3.25) 0.08 
 <7 462 (85.2) 58 (77.3) 1    
Ethnicity       
 Tajik 252 (46.5) 35 (46.7) 1    
 Pashtoon 105 (19.4) 16 (21.3) 1.09 (0.58–2.06) 0.77 0.80 (0.40–1.60) 0.54 
 Uzbek 62 (11.5) 10 (13.3) 1.16 (0.54–2.47) 0.69 1.04 (0.47–2.31) 0.91 
 Hazara 89 (16.4) 11 (14.7) 0.88 (0.43–1.82) 0.75 0.81 (0.38–1.72) 0.58 
 Other 34 (6.3) 3 (4.0) 0.63 (0.18–2.17) 0.47 0.48 (0.13–1.75) 0.27 
Received antimicrobial drugs before hospitalization      
 Yes 476 (87.8) 65 (86.7) 1.09 (0.47–2.49) 0.83   
 No 56 (10.3) 7 (9.3) 1    
 Unknown 10 (1.9) 3 (4.0) 2.4 (0.52–10.9) 0.24   
Bacillus Calmette–Guérin vaccine       
 Received 474 (87.4) 55 (73.3) 0.39 (0.22–0.69) <0.01 0.47 (0.25–0.88) 0.02 
 Not received 68 (12.6) 20 (26.7) 1    
>1 dose pentavalent vaccine, n = 547†       
 Received 380 (79.0) 44 (66.7) 0.53 (0.30–0.92) 0.02   
 Not received 101 (21.0) 22 (33.3) 1    
Measles vaccine, n = 165†       
 Received 98 (64.9) 6 (42.9) 0.40 (0.13–1.23) 0.11   
 Not received 53 (35.1) 8 (57.1) 1    
Vitamin A, n = 336†       
 Received 111 (37.1) 7 (18.9) 0.39 (0.16–0.92) 0.03   
 Not received 188 (62.9) 30 (81.1) 1    
Malnutrition‡       
 Detected 199 (36.7) 41 (54.7) 2.06 (1.26–3.35) <0.01 2.06 (1.22–3.49) <0.01 
 Not detected 340 (62.7) 34 (45.3) 1    
Anemia       
 Detected 246 (45.4) 39 (52.0) 1.32 (0.76–2.29) 0.31   
 Not detected 192 (35.4) 23 (30.7) 1    
 Not evaluated 104 (19.2) 13 (17.3) 1.04 (0.50–2.14) 0.90   
*Age, sex, ethnicities, and variables with p<0.2 in univariate analyses were included in multivariate analysis; blank cells indicate variables without p<0.2 in 
univariate analysis. Because they had collinearity, bacillus Calmette–Guérin vaccine was included with vaccines and vitamin A was included in 
multivariate analysis.  
†No. children eligible for the vaccines or vitamin A. 
‡3 children, whose nutritional status was unknown, were excluded. 
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